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Molecular wires comprising a Ru(II)- or Re(I)-complex head group,
an aromatic tail group, and an alkane linker reversibly inhibit the
activity of the copper amine oxidase fromArthrobacter globiformis
(AGAO), with Ki values between 6 M and 37 nM. In the crystal
structure of a Ru(II)-wire:AGAO conjugate, the wire occupies the
AGAO active-site substrate access channel, the trihydroxypheny-
lalanine quinone cofactor is ordered in the ‘‘off-Cu’’ position with
its reactive carbonyl oriented toward the inhibitor, and the ‘‘gate’’
residue, Tyr-296, is in the ‘‘open’’ position. Head groups, tail-group
substituents, and linker lengths all influence wire-binding interac-
tions with the enzyme.
diimine  topaquinone  metalloenzyme  active site
Copper and quinone containing amine oxidases (EC 1.4.3.6)catalyze the oxidative deamination of primary amines to the
corresponding aldehydes with concomitant generation of am-
monia and hydrogen peroxide.
RCH2NH2  O2  H2O3 RCHO NH3  H2O2.
Each subunit of these homodimeric enzymes contains a deeply
buried active site comprised of a single type II (‘‘non-blue,’’
square-pyramidal) copper atom and an organic cofactor, 2,4,5-
trihydroxyphenylalanine quinone (topaquinone orTPQ) (1, 2). The
finding that the human vascular adhesion protein (HVAP-1) is a
copper amine oxidase (CuAO) has heightened interest in the
mechanism and inhibition of these enzymes (3). With the potential
for therapeutic applications, research has focused on elucidation of
the factors that govern inhibitor sensitivity and selectivity.
We are exploring the potential of channel-blocking metal–
diimine wire complexes to function as highly selective inhibitors of
CuAOs. We chose phenylethylamine oxidase from Arthrobacter
globiformis for initial study, owing to its ease of expression and
purification as a C-terminal Strep-tag II fusion protein (4). Our
choice of metal–diimine wires was based on the results of extensive
investigations of their conjugates with cytochrome P450cam, which
have revealed structural features of conformational states that
likely are involved in steps of the catalytic cycle of the enzyme (5–9).
Similar molecular wires have been used in attempts to measure the
reduction potentials of deeply buried protein cofactors; indeed, in
experiments of relevance here, a diethylaniline-tipped triphenylene
wire coupled to a gold electrode allowed electrochemical charac-
terization of Arthrobacter globiformis amine oxidase (AGAO) co-
factor TPQ (10). Binding of the wire in the active-site channel was
not established independently but could be inferred from the
efficiency of electron tunneling from the electrode to the buried
cofactor.
We have designed and synthesized a series of highly potent
channel-blocking inhibitors of AGAO. The crystal structure of a
Ru-wire:AGAO conjugate clearly demonstrates that the wire re-
sides in the active-site channel; it also reveals key aspects of
active-site topology and conformational mobility. Furthermore,
variations in binding in response to changes in wire sensitizer,
substrate, and linker compositions have led to particularly powerful
AGAO inhibitors.
Materials and Methods
Syntheses. The synthesis of the [Ru(II)(bpy)2(phen)] complexes is
shown in Scheme 1, where bpy stands for 2,2-bipyridine and phen
stands for 1,10-phenanthroline. The details for a representative
complex, [Ru(II)(bpy)2(phen)-C4-DMA] (5a), where DMA stands
for dimethylaniline, and its precursors are given below. The syn-
theses of the other compounds reported in this work and their
precursors may be found in Supporting Text, which is published as
supporting information on the PNAS web site. All syntheses were
conducted under a nitrogen atmosphere by using standard Schlenk
techniques and degassed solvents. Dimethylformamide and tetra-
hydrofuranwere dried before use by passing through activated silica
columns. All other solvents were obtained in omnisolv grade from
EM Biosciences (San Diego) and used as received. We prepared
4-methyl-4-chloromethyl-bpy and 2,2,3,3,4,5,5,6,6-nonafluoro-
4-(phenylethynyl)-1,1-biphenyl (11) according to procedures de-
scribed in refs. 11 and 12. Cesium carbonate was dried by heating
at 250°Cunder vacuum just before use.All other reagentswere used
as received from Aldrich unless otherwise noted. All product
work-up procedures were performed in air. All metal complexes
decompose over several days on standing in airlight. They were
stored in the dark under argon at 5°C until just before use.
Spectra. NMR spectra were obtained by using a Varian Mercury
300 spectrometer. Mass spectra were obtained by using a LCQ
quadropole ion trap mass spectrometer (Finnigan-MAT, San Jose,
CA). Electronic spectra were obtained by using a Hewlett–Packard
8452 diode array spectrometer. Steady-state fluorescence spectra
were collected by using a K2 fluorimeter (ISSS, Champaign, IL)
with excitation at 450 nm for Ru(II) complexes and 355 nm for 10.
m-Br-(CH2)3-OC6H4NMe2 (3a).A stirredmixture of 1.0 g (7.3 mmol) of
m-dimethylaminophenol, 6.5 g (20mmol) ofCs2CO3, and 5.0ml (10
g, 50mmol) of 1,3-dibromopropane in 20ml of dimethylformamide
was heated at 45°C for 3 h. Solvent and excess 1,3-dibromopropane
Abbreviations: AGAO, Arthrobacter globiformis amine oxidase; CuAO, copper amine
oxidase; bpy, 2,2-bipyridine; phen, 1,10-phenanthroline; DMA, dimethylaniline; TPQ,
2,4,5-trihydroxyphenylalanine quinone.
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in the Protein Data Bank, www.pdb.org (PDB ID code 2BT3).
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were removed under vacuum. The product was separated from the
residue by using silica gel chromatography with CH2Cl2hexanes
(2575 volvol) as the eluent. Removal of solvent under vacuum
gave the product as a colorless solid. Yield: 1.6 g (85%). 1H NMR
(300 MHz, CD2Cl2):  2.29 (tt, J  6.6, 5.7 Hz, 2H), 2.92 (s, 6H),
3.62 (t, J 6.6 Hz, 2H) 4.08 (t, J 5.7 Hz, 2H), 6.21–6.27 (m, 2H),
6.35 (m, 1H), 7.11 (m, 1H). ESI-MS (MeOH) mz: 258 (MH).
4-(m-(CH2)4-OC6H4NMe2)-phen (4a). A solution of 1.2 g (6.0 mmol) of
4-methylphenanthroline in 25 ml of tetrahydrofuran was treated
with dropwise addition of 3.0 ml of 2.0 M Li(NiPr2) in tetrahydro-
furanheptaneethylbenzene. The resulting black solution was al-
lowed to stir for 30 min and then was added dropwise to 1.54 g (6.0
mmol) of 3a over 20 min. The reaction was allowed to proceed for
12 h and then quenched by addition of 5 ml of EtOH and 3 ml of
H2O. Solvent was removed under vacuum, and the residue was
chromatographed on silica by using 1090 MeOHCH2Cl2 eluant.
In some cases, a second silica column (1090 MeOHCH2Cl2) was
used to further purify the product. Fractions containing pure
product were pooled to give the crude product as a waxy solid. The
product was extracted with 25 ml of Et2O to remove impurities and
give the product as a white powder. Yield: 0.75 g (33%). 1H NMR
(300 MHz, CD2Cl2):  1.9–2.1 (m ,4H), 2.90 (s, 6H), 3.3 (m, 2H,
partially obscured by CD2HOD signal), 4.05 (m, 2H), 6.26 (m, 2H),
6.36 (m, 1H), 7.05 (m, 1H), 7.62 (d, 1H), 7.74 (dd, 1H), 7.91 (d, 1H),
8.17 (d, 1H), 8.41 (dd, 1H), 8.94 (d, 1H), 9.07 (d, 1H). ESI-MS
(MeOH) mz: 372 (MH).
{Ru(bpy)2[4-(m-(CH2)4-OC6H4NMe2)-phen]}(NO3)2 (5a). A mixture of
0.48 g (1.0 mmol) of cis-Ru(bpy)2Cl2 and 370 mg (1.0 mmol) of
4-m-(CH2)4-OC6H4NMe2-phen (4a) in 10 ml of 2080 EtOHH2O
was heated at reflux for 12 h. Solvent was removed under vacuum,
and the residue was purified by silica chromatography (2 40 cm)
using KNO3 saturated 151570 (volvolvol) H2OEtOHMeCN
eluent. For 5d, the crude product required further purification,
which was effected by two additional silica gel chromatography
steps by using KNO3 saturated H2OEtOHMeCN (5590 vol
volvol) eluent. This process resulted in partial separation of the
desired product. Fractions containing ‘‘pure’’ product, as deter-
mined by TLC and electrospray ionization-MS, were pooled, and
solvent was removed under vacuum. The product was extracted
from the resulting residue by using 20 ml of 2080 (volvol)
MeOHCH2Cl2. Removal of solvent gave the product as a red
powder. The reported yield is low because a significant quantity of
product was also present in the impure product fractions from the
chromatographic separations. Yield: 0.27 g (31%). 1H NMR (300
MHz, CD3OD):  1.85–2.05 (m, 6H), 2.9 (s, 6H), 4.06 (t, J 5.7Hz,
2H), 6.21–6.24 (m, 2H), 6.35 (ddd, J 7.8,1.8, 0.5 Hz, 1H), 7.05 (m,
1H), 7.30 (m, 2H), 7.53 (m, 2H), 7.61 (m, 2H), 7.72 (d, J 5.5 Hz,
1H), 7.81 (dd, J 8,5 Hz, 1H), 7.93 (d,J 5.5 Hz, 2H), 8.0–8.1 (m,
3H), 8.12–8.2 (m, 3H), 8.29 (d, J 9Hz, 1H), 8.51 (d, J 9Hz,1H),
8.58 (dd, J 7,0.7Hz, 1H), 8.7 (m, 3H). ESI-MS (MeOH)mz: 847
(M-NO3), 784 (M-2NO3-H).
Crystallization of the [Ru(II)phen-C4-DMA]–AGAO Complex. AGAO
was purified as described in ref. 4. Crystals of AGAO were grown
by the hanging-drop vapor diffusion method. Each drop comprised
protein (2 l, 10 mgml) mixed with an equal volume of well
solution (700 mM ammonium sulfate150 mMNa citrate, pH 6.5).
Crystals appeared after several weeks at room temperature. Cryo-
protection and addition of wire were performed simultaneously by
progressively soaking a crystal in well solutions (30 l) containing
[Ru(II)phen-C4-DMA] (5 mM, 25-fold molar excess) and in-
creasing concentrations of glycerol (2.5% increments to 30%
volvol) over a 24-h period. The concentration of wire was kept
constant throughout these changes. The crystal was flash-frozen in
a 100 K N2 gas stream.
X-Ray Data. Diffraction images were recorded on a Mar345 image
plate detector with x-rays from a RU-200 rotating anode generator
(Rigaku, Tokyo) (Cu K, 1.5418 Å) with mirror optics fromOsmic
(Auburn Hills, MI). Diffraction data were indexed and scaled by
using the HKL software suite (13). Details are set out in Table 1.
Crystal Structure Refinement.The startingmodel for refinement was
the native AGAO structure refined at 1.60 Å resolution (D.B.L.,
A.P.D., H.C.F., and J.M.G., unpublished results). No solvent mol-
ecules, metal ions, sulfate ions, or glycerol molecules were included.
Residues with multiple conformers in the native structure were
assigned zero occupancy, and the active-site TPQ (residue 382) was
replaced by an Ala residue. Initial low-resolution (15 to 4 Å)
rigid-body refinement was followed by rounds of restrained refine-
ment with translation, libration, and screw-motion parameteriza-
tion (14), alternating with the inspection of electron-density maps
and manual adjustment of the model. Solvent atoms and the Cu
atomwere added to themodel gradually, consistent with difference
Scheme 1.
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electron density and reasonable stereochemistry. The TPQ side
chain, which was clearly defined, was modeled in the ‘‘off-Cu’’
conformation. Solvent atoms in the active-site channel were added
last. At a late stage of the refinement, there were two significant
difference electron-density features in the active-site channel. One
such feature was adjacent to the TPQ and could be modeled as the
DMA group of the [Ru(II)phen-C4-DMA] wire (see Fig. 2c). The
other,more intense, difference electron-density feature was located
at the entrance to the active-site channel and could be resolved as
two peaks separated by 2.9 Å. Two large anomalous difference
peaks occurred at the same positions (see Fig. 2c), the larger being
equal to an anomalous difference peak at the Cu atom site and the
other being 50% smaller. These peaks were interpreted as
alternative sites for the Ru atom, the positions of the phen and bpy
ligand groups being inferred from known molecular geometries.
The chiral Ru(II) head group was arbitrarily modeled as the 
enantiomer.
The hypothesis that there were two slightly different Ru
positions implied that the wire has at least two conformers. No
significant electron density was observed between the DMA and
Ru ends of the wire (see Fig. 2c). Nevertheless, it was possible
to fit plausible models of the –(CH2)4– linker into the active-site
channel (see Fig. 2b).
The occupancies of the atoms at the DMA and Ru ends of the
wire were varied systematically until the residual electron density
was optimized. In the finalmodel, the occupancy of theDMAgroup
was 1.0, whereas the occupancies of the two Ru atoms and their
ligand groups were 0.3 and 0.2, respectively.
The x-ray data and refinement statistics are presented in Table
1. The coordinates and structure factors of the complex have been
deposited in the Protein Data Bank (PDB ID code 2BT3).
Crystallographic Software. The monomer library for the [Ru(II)-
phen-C4-DMA] wire was constructed by using a combination of
PRODRG (15), the CCP4 molecular library sketcher (16), andmanual
parameter adjustment. Solvent atoms were placed at positions
indicated by ARP/WARP (17) andor evidence from difference
density peaks. Least-squares refinement was carried out with
REFMAC5 (18). The final structurewas validated by using PROCHECK
(19) and MOLPROBITY (20). Figs. 2 and 3 were produced by means
of PYMOL (21) and LIGPLOT (22), respectively.
Inhibition Experiments. Amine oxidase activity was determined by
monitoring benzaldehyde production over the course of 3 min at
Fig. 1. AGAO inhibitors.
Table 1. Crystallographic data and structure refinement statistics
for the conjugate of [Ru(II)phen-C4-DMA] with AGAO
Crystallographic data
Space group C2
Unit cell dimensions
a, Å 158.06
b, Å 62.91
c, Å 92.10
, ° 112.11
Data collection temperature, K 100
Resolution, Å 1.73–15.0 (1.73–1.76)†
Mosaicity, ° 0.38
Observations, total 316,679
Observations, unique 82,062
Redundancy 3.9 (2.7)
Rmerge‡ 0.041 (0.105)
I(I) 22.5 (5.8)
Completeness, % 94.4 (85.2)
Refinement statistics
Resolution range, Å 1.73–15.0 (1.73–1.78)
Nonhydrogen atoms used in refinement 5,510
Components of model
Protein Residues 9–628
Metal atoms Cu, Na, Ru
Water molecules 508
Other [Ru(II)phen-C4-DMA],
3SO4
2, 6 glycerol
Reflections in working set 77,947 (5,056)
Reflections in free set 4,106 (266)
Rwork§ 0.154 (0.183)
Rfree¶ 0.171 (0.213)
Rtotal 0.155
rmsd bond lengths, Å 0.011
rmsd bond angles, ° 1.5
B value from Wilson plot, Å2 20.3
Average B value, Å2 15.6
ESU, Å 0.053
Ramachandran plot residues in††
Most favored regions, % 90.1
Additionally allowed regions, % 8.7
Generously allowed regions, % 0.4 (Lys-242 and Phe-142)
†Values in parentheses are for the highest resolution shell.
‡Rmerge  Ih  	Ih
	Ih
.
§R values  FobsFcalcFobs.
¶5% of the reflections were reserved for the calculation of Rfree.
Estimated standard uncertainty in atomic position, based on maximum like-
lihood (35).
††Calculated by using PROCHECK (19).
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25°C by using 250  12,800 M1cm1 (23). All kinetics experi-
ments were carried out in 0.1 M potassium phosphate buffer (pH
7.2). Kinetics analysis involved first equilibrating each enzyme with
a given amount of inhibitor for 1 min under magnetic stirring,
followed by addition of substrate benzylamine to initiate each assay.
Assays were run in duplicate or triplicate at several inhibitor
concentrations. Data were fit to theMichaelis–Menten equation by
using ORIGIN software (Version 7.0, Microcal, Amherst, MA).
Steady-state kinetics data were collected on a Hewlett–Packard
8453 diode-array spectrophotometer equippedwith a thermostated
cell chamber connected to an Endocal RTE-5 circulating water
bath. Solutions of the Ru wires were prepared in H2O by using
455  14,500 M1cm1. A stock solution of [Ru(II)phen-C4-
DMA] was prepared in absolute ethanol by using 252  29,000
M1cm1. N,N-dimethyl-m-anisidine (Acros Organics, Geel, Bel-
gium) was distilled before use, and a stock solution was made up in
acetonitrile. A stock solution of C11–DMA (see Fig. 1; compound
11) was prepared in dimethylformamide. Because of the limited
solubility of several inhibitors, it was necessary to run control assays
in the presence of the stock-solution solvents to exclude the
possibility that these solvents act as inhibitors. Ethanol, acetonitrile,
and dimethylformamide were shown not to affect the rate of amine
oxidation at concentrations comparable with those used during
kinetics experiments.
Treatment of kinetics data for a competitive inhibitor was
performed according to Segel (24). Inhibition constants are calcu-
lated from a linear plot of KMapparent vs. [I] where the x-intercept is
equal to Ki.
Results and Discussion
The 10 wires are shown in Fig. 1. The initial wire design
incorporated a DMA substrate to anchor the probe in the active
site. Alkane linkers optimize conformational f lexibility, thereby
allowing the wires to fit well in the substrate channel. The linker
length was varied from 1 to 11 methylene units, and
[Ru(II)(bpy)2(phen)]2, [Re(I)(CO)2(N-MeIm)(phen)], and
CH3 head groups were investigated. The role of the dimethyl-
amino group on inhibitor binding was probed in experiments by
using the phenyl analogue of m-DMA.
The ability of the Ru(II) and Re(I) complexes to act as fluores-
cence probes of AGAO binding was evaluated by both steady-state
and time-resolved emission spectroscopy.Wire emission properties
(see Table 3, which is published as supporting information on the
PNASweb site) are similar to those for [Ru(II)(bpy)2(phen)]2 and
[Re(I)(CO)3(N-MeIm)(phen)], indicating that there is no internal
quenching by theDMAgroup in any of the complexes. As expected
from the lack of overlap between wire emission and TPQ absorp-
tion, the emission spectrum of each wire:AGAO conjugate is
virtually identical with the corresponding wire spectrum.
Crystal Structure of the [Ru(II)phen-C4-DMA]–AGAOComplex. [Ru(II)-
phen-C4-DMA] occupies the active-site channel of each subunit of
the homodimeric AGAOmolecule. There is no deviation from the
crystallographic twofold symmetry of themolecule, and the present
crystallographic data do not permit us to conclude whether the two
channels are occupied symmetrically.Within the limits of precision,
the structure of the protein in the wire complex is identical to the
structure of the native protein (25). The TPQ ring, which is
disordered in many CuAO structures and is bound to the Cu atom
in some of them, is fully ordered in the off-Cu position. It is directed
toward the active-site channel, as would be required for interaction
with a substrate. In agreement with other AGAO structures where
the TPQ is in the off-Cu position (D.B.L., unpublished results), the
so-called gate residue Tyr-296 is in the ‘‘open’’ position.
The DMA group lies close to the TPQ cofactor in a pocket lined
by nine hydrophobic residues (see Figs. 2 and 3). There are contacts
Fig. 2. Crystal structure of the wire–AGAO complex. (a) The AGAO molecule, showing the [Ru(II)phen-C4-DMA] wire inserted in the active-site channel of each
subunit. The two subunits of the homodimeric AGAO molecule are colored gray and brown, respectively. (b) The interaction between the [Ru(II)phen-C4-DMA]
wire and the AGAO molecule. The [Ru(II)(phen)(bpy)2] head group lies at the protein–solvent interface and fills the opening of the active-site channel. The DMA
group makes close (3 Å) contacts with the TPQ cofactor. The –(CH2)4– linker is disordered; it is shown in one of its modeled conformations. (c) Electron-density
contours and the model of the [Ru(II)phen-C4-DMA]–AGAO complex. The wire is fitted to Fo  Fc electron density (green) contoured at 3. The TPQ cofactor is
shown in 2Fo  Fc electron density (gray) contoured at 1.5. Anomalous difference electron density (blue) is contoured at 4.5.
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of3 Å between the two DMAC(methyl) atoms and the TPQO5
atom, and the aromatic ring plane of the DMA group lies at 70°
from the plane of the TPQ ring (Fig. 2c). The position of the DMA
group in relation to the TPQ is the same as that of the methylphe-
noxy moiety in the covalent adduct of AGAO with the inhibitor
4-(4-methylphenoxy)-2-butyn-1-amine (15). In other complexes of
AGAO with covalently bound aromatic inhibitors, the aromatic
ring lies in the same position (D.B.L., A.P.D., H.C.F., and J.M.G.,
unpublished results).
The [Ru(II)(phen)(bpy)2] head group of the wire nestles into the
opening of the active-site channel (Fig. 2), making relatively few
contacts with the protein. Evidence from difference electron den-
sity and anomalous difference electron-density maps indicates that
the Ru complex is distributed over two locations. It is possible that
these locations correspond to the enantiomers ( and ) of the
[Ru(II)(phen)(bpy)2] head group. Experiments should be con-
ducted to test this hypothesis. If the Ru complex is distributed over
two sites, then the portion of the wire linking the Ru complex and
theDMAgroupmust have at least two conformations. The inferred
disorder is consistent with the following observations: the –(CH2)4–
linker is not represented by significant electron density; the refined
occupancies of the twoRu sites (0.3, 0.2) are significantly lower than
the occupancy of the more tightly anchored DMA group (1.0); and
the Ru complex is relatively unrestrained by contacts with the
protein.
Inhibition of the Enzyme. Over the past few years, there has been
increasing interest in the development and assessment of amine
oxidase inhibitors (26–34). The results of these studies have un-
derscored the importance of structural differences among the active
sites of CuAOs in governing reactivity with a given inhibitor
(29–32). Other recent results also suggest that it may be feasible to
design selective mechanism-based CuAO inhibitors. In the crystal
structure of AGAO, the active-site channel and pocket are lined by
13 hydrophobic residues (25). When an inhibitor, 4-(2-naphthyl-
oxy)-2-butyn-1-amine, was modeled into the AGAO active site as
a Schiff base derivative, it made significant contacts with 5 of these
residues (Phe-105, Trp-168, Tyr-302, Tyr-307, and Trp-359), and
Fig. 3. A Ligplot cartoon (19) representing the contacts between [Ru(II)-
phen-C4-DMA] and residues in the AGAO active-site channel. The atoms or
residue involved in a contact are indicated by ‘‘hairs’’ on the relevant circle.
Residue Leu 358* is marked with an asterisk to indicate that it belongs to the
second subunit of the homodimeric molecule.
Fig. 4. Inhibition of AGAO by [Ru(II)phen-C4-DMA]. (a) Kinetics raw data fit
to a Michaelis–Menten model. Legend shows the concentration of inhibitor
used for each curve. Error bars represent standard deviation of the rate at the
given benzylamine concentration. (b) The Ki plot for [Ru(II)phen-C4-DMA].
Error bars represent the error associated with the hyperbolic fits in a.
Fig. 5. Inhibition constant vs. linker length for Ru(II)–diimine wires.
Table 2. AGAO inhibition constants
Inhibitor Ki
(2) [Ru(II)bpy-C1-DMA] 300  18 nM
(5a) [Ru(II)phen-C4-DMA] 37  3 nM
(5b) [Ru(II)phen-C5-DMA] 43  1.5 nM
(5c) [Ru(II)phen-C6-DMA] 80  11 nM
(5d) [Ru(II)phen-C9-DMA] 92  9 nM
(5e) [Ru(II)phen-C11-DMA] 92  11 nM
(8) [Ru(II)phen-C4-OPh] 680  35 nM
(10) [Re(I)phen-C4-DMA] 195  8 nM
(11) C11-DMA 6  1 M
N,N-dimethyl-m-anisidine 8  1 M
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the possibility of -stacking interactions with the side chains of
Phe-105 and Tyr-302 was noted (29). Structural and kinetics studies
of the interaction between AGAO and 4-(aryloxy)-2-butynamines
have provided further details of the active-site residues that may
affect substrate binding (31).
All eight metal–diimine wires strongly inhibit AGAO (Table 2).
Inhibition is completely reversible with dialysis resulting in full
recovery of enzymatic activity. Representative Michaelis–Menten
and Ki plots are given in Fig. 4. All inhibitors exhibit clean
competitive inhibition with respect to substrate amine, indicating
that they block the AGAO active-site channel or otherwise inter-
fere with binding of substrate amine to the free enzyme. Active-site
blocking is demonstrated by the structural analysis of [Ru(II)phen-
C4-DMA]–AGAO (Fig. 2). The inhibitor is capable of making
contacts of 3–5 Å with up to nine residues in the active-site channel
and pocket (Fig. 3), including the five near-neighbor residues
identified earlier in simulations of 4-(2-naphthyloxy)-2-butyn-1-
amine-AGAO active-site complexes (29).
[Ru(II)phen-C4-DMA] is themost potent inhibitor (Ki 37nM).
When the [Ru(II)(bpy)2(phen)]2 head group is replaced by
[Re(I)(CO)3(N-MeIm)(phen)] (Fig. 1; compound 10) the Ki
increases5-fold to 195 nM. If the head group is omitted altogether
in aDMAwire with an 11-carbon linker (Scheme 1; compound 11),
the Ki increases further to 6 M. A similar result is obtained with
the ligand N,N-dimethyl-m-anisidine, which has a Ki of 8 M. It is
possible that the head group interacts with the protein surface in a
way that stabilizes the protein–inhibitor complex. The interaction
may be either electrostatic or hydrophobic or both. In AGAO, the
molecular surface surrounding the entrance to the active-site
channel is predominantly negative (25). A wire with a Ru(II) head
group (charge 2) should bind better than one with a Re(I) head
group (charge1) or a wire with no head group, as observed. The
hydrophobic surfaces of the head groups decrease in the sameorder
as the charges, which also may provide an explanation for the trend
in binding. In the crystal structure of the [Ru(II)phen-C4-
DMA]:AGAOconjugate, contacts between the head group and the
protein are clearly important (Fig. 3c), but the quality of the
electron-density maps does not enable us to discriminate between
electrostatic and other types of interaction.
The importance of theTPQ-contacting tail group is illustrated by
the increase in Ki when the dimethylamine group of DMA is
replaced by a hydrogen atom: the Ki of [Ru(II)phen-C4-OPh] (680
nM) is 18-fold greater than that of [Ru(II)phen-C4-DMA] (37 nM).
However, the finding that [Ru(II)phen-C4-OPh] inhibits AGAO at
a submicromolar level shows that the dimethylamine group is not
essential for binding.
In contrast to head (Ki ratios 200:1) and tail (Ki ratios 18:1)
groups, the linker length plays a comparatively minor role (Fig. 5).
The potency decreases only slightly as the linker length increases
from –(CH2)4– to –(CH2)11–. The greatest variations within this
range occur from –(CH2)4– to –(CH2)6–. We assume that the wires
with shorter linkers have more ordered structures and that in wires
withmore than six methylene groups the head group is too far from
the molecular surface to affect the interaction. Only the wire with
a –(CH2)1– linker, which is too short to permit the DMA group to
approach TPQ when the Ru(II) complex is at the surface of the
protein molecule, is a relatively poor inhibitor.
Our channel-blocking wires include the most effective reversible
CuAO inhibitors reported to date. What is more, we have made
progress in understanding some of the structural subtleties that
determine inhibitor potency.Most importantly, our wires target the
active-site channel tracing the path of a substrate from the solvent
to the active site. In these AGAO–wire conjugates, the tertiary
amine terminus is in close proximity to the off-Cu cofactor TPQ.
Because active-site channel residues vary substantially among
CuAOs, carefully designed metallowires could function as highly
selective inhibitors. Based on findings with different head groups,
tail-group substituents, and linkers, we predict that selective CuAO
inhibitors with picomolar affinities will be available in the near
future.
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